Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
By S. Demo, C. Kirk, M. Aujay, T. Buchholz, M. Dajee, M. Ho, Jing Jiang, Guy J. Laidig, E. Lewis, F. Parlati and 7 more. Cancer Research, 2007
655 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/c59f094da6efa45e4d39bee529c801f9a65aa738
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
Citations in the corpus
- A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis (2009, background): “However, most well characterized proteasome inhibitors mediate equivalent inhibition of both proteasome chymotrypsin-like activities (β5 and LMP7”
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. (2012, background): “Prior lines of therapy, median (range) 5 (1-20)”